
Type 2 asthma is a common phenotype of asthma, characterized by key cytokines IL-4, IL-13, and IL-5, as well as elevated type 2 inflammatory biomarkers as FeNO, and eosinophils, or the need for maintenance OCS. Type 2 inflammation is evident in up to 88% of patients with severe asthma, representing a substantial portion of the disease burden associated with asthma. Explore the resources below better understand the role of type 2 inflammation in asthma.

Join Dr. Hanania to understand how to identify patients at risk of fixed airway obstruction in clinical settings.

This video clip from the EAACI 2024 symposium highlights that a multidisciplinary approach is essential for the treatment of asthma.

Dr Mario Castro presents the latest clinical data on biologics showcasing their effect on airway remodeling parameters and airway hyperresponsiveness in patients with severe asthma.
Professors Celeste Porsbjerg and Klaus Rabe and Dr Mario Castro discuss disease modification in severe asthma, including what disease modification is, how it can be identified, and how the advent of biologics may bring about disease modification.

Professor Klaus Rabe shares a patient case highlighting the burden of disease associated with airway remodeling and discusses practical aspects of identifying and managing airway remodeling in severe asthma patients with Professor Porsbjerg and Dr Castro.

The ADVENT program will present four symposia sharing the latest science in asthma and COPD at the 2024 European Respiratory Society (ERS) Congress. Visit Booth #A4.02 to learn more about ADVENT.

Professor of Severe Asthma, Bispebjerg Hospital Copenhagen, Denmark
Associate Professor of Medicine, University of Minnesota; Physician Minneapolis VA Health Care System; Partner, St. Paul Allergy & Asthma, PA

Join Sanofi and Regeneron for an educational symposium on type 2 inflammation processes underlying pediatric asthma, atopic dermatitis, and eosinophilic esophagitis.
Professor Couillard is a respirologist and the Québec Lung Association Chair of Respiratory Research at the Université de Sherbrooke, Canada. He leads a team investigating ways to use biomarkers to predict and prevent asthma attacks and improve asthma management.

Dr. Lugogo is a Professor of Medicine in the Division of Pulmonary, Critical Care Medicine and is the Director of the Michigan Medicine Asthma Program. She is also the Program Director of INHALE, a statewide collaborative quality improvement program that focuses on improving the care of patients with asthma and COPD in Michigan.